Trial Profile

A phase 3 study of Latiglutenase (IMGX003) for Treatment of Celiac Disease

Status: Planning

Phase of Trial: Phase III

Latest Information Update: 21 May 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Latiglutenase (Primary)
Indications Coeliac disease
Focus Registrational; Therapeutic Use
Sponsors ImmunogenX

Most Recent Events

16 May 2024 According to a Entero Therapeutics media release, company First Wave BioPharma Changes Name to Entero Therapeutics.
14 Mar 2024 According to a First Wave Biopharma media release, ImmunogenX has been acquired and merged into First Wave Biopharma.
14 Mar 2024 According to a First Wave Biopharma media release, this Phase 3 clinical development plan for latiglutenase has been reviewed by the GI Division of the U.S. Food and Drug Administration (FDA) at the End of Phase 2 meeting with an agreed plan forward, with initiation of the Phase 3 trials expected to begin in early 2025.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com